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in Dentistry at Virginia Commonwealth University. 
Virginia Commonwealth University 2018 
 
Major Director: Dr. Janina P. Lewis, Director of Faculty Advancement, Professor of Oral and 
Craniofacial Molecular Biology, Philips Institute, School of Dentistry 
 
 
Abstract: Periodontitis is an inflammatory disease of the oral cavity induced by anaerobic 
bacteria, that remains to be the primary cause of tooth loss in adults worldwide. Finding an anti-
microbial therapeutic to selectively target periodontal pathogens has proven to be difficult, and 
current treatment modalities only provide a transient benefit.  Amixicile is a non-toxic, readily 
bioavailable novel antimicrobial that targets strict anaerobes through inhibition of the activity of 
Pyruvate Ferredoxin Oxidoreductase (PFOR), a major enzyme mediating oxidative 
decarboxylation of pyruvate, a critical step in metabolism. Our study aimed to evaluate the 
efficacy of amixicile in inhibiting the growth of bacteria harvested from the complex sub-
gingival biofilm of patients with chronic periodontitis. We hypothesize that amixicile will 
selectively inhibit pathogenic anaerobic bacteria collected from patients, with the same efficacy 
as metronidazole, the current accepted treatment modality.   
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Plaque samples were harvested from patients with severe chronic periodontitis and cultured 
under anaerobic conditions.  The microbiomes were grown in the presence of amixicile and 
metronidazole and the growth was compared to that of bacteria grown in the absence of the 
antimicrobials. Following 24 hour incubation, bacterial DNA was isolated and bacterial quantity 
was evaluated by quantitative PCR (qPCR) using primers specific for 12 bacterial species: P. 
gingivalis (Pg), P. intermedia (Pi), F.nucleatum (Fn), S.gordonii (Sg), S. anginosus (Sa), V. 
atypical (Va), L. acidophilus (La), A.actinomycetemcomitans (Aa), T.denticola (Td), S.mutans 
(Sm), S.sanguis (Ss), and 16s.  Individual qPCR runs were combined to represent an overall 
average of CT value differences.  
 
Amixicile treatment groups exhibited statistical significant reductions (P<.001) for several 
anaerobic bacteria: P. intermedia,  F. nucleatum  and Veillonella atypical. When comparing 
amixicile to metronidazole, amixicile performed with similar efficacy with the largest effect seen 
for PFOR bacteria.  Our conclusion supports amixicile as a potent inhibitor of anaerobic bacteria, 
and could be a potential new therapeutic antimicrobial in the treatment of periodontal disease. 
 
 
 
Keywords: amixicile, metronidazole, mico-biofilms, periodontitis, q-PCR analysis 
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INTRODUCTION 
Chronic periodontitis is an inflammatory disease of the oral cavity, induced by bacterial biofilm 
in a susceptible host. Research conducted in the last decade has revealed the complexity of this 
oral bacterial biofilm, it can no longer be viewed as a conglomeration of bacteria attached to the 
diseased root surface.  Rather it is an organized and structured three-dimensional assembly of 
over 600 bacterial species, which develop multicellular units forming specific scaffolds and 
passageways allowing for fluid flow for nutrition and capacity to share genes for antibiotic 
resistance1.  Furthermore, there appears to be a sequential acquisition of certain species within 
the biofilm that lay the framework for greater pathogenic potential2.  Keystone pathogens such as 
Porphyromonas gingivalis can therefore play a significant role in orchestrating pathogenesis 
while only making up a fraction of the biofilm population3,4.  These bacteria produce pro-
inflammatory antigens and virulence factors such as lipopolysaccharide (LPS), altering the local 
environment to one more suitable for disease progression4.  Once the host response modulation is 
initiated, the inflammation can spread beyond the marginal gingiva, lead to irreversible 
destruction of tooth supporting tissues and ultimately bone loss5.  
 
In fact, classic studies have already demonstrated that dental plaque and calculus are major 
etiologic agents in the progression of periodontal disease6, even before the mechanism was 
completely understood.  With an increase in the quantity of bacteria in the oral cavity, there is a 
shift in the microflora.  In health, the predominant bacterial species is aerobic gram-positive 
cocci which includes the Streptococcus species. However, in periodontitis the predominant 
species are anaerobic gram-negative rods which include organisms such as Porphyromonas 
gingivalis, Prevotella intermedia, Fusobacterium nucleatum, and Tannerella forsythia7,8.  
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Disease progression in periodontitis can best be described by the polymicrobial synergy and 
dysbiosis model.  In this model, colonizing bacteria form communities that with the aid of the 
host inflammatory system, can enhance the colonization and/or virulence of other bacteria 
(polymicrobial synergy).  Eventually this results in a dysbiotic community, a state of imbalance 
in the relative abundance and influence of certain species on the inflammatory response.  In a 
susceptible host, a profound and “ill advised” immune response allows the biofilm to cause 
enough inflammation to cause irreversible damage to the local environment4.  During an 
inflammatory response, there is an activation of T and B cells along with an increase in the 
production cytokines, chemokines, and other mediators.  Ultimately, expression levels of a 
protein called receptor activator of nuclear factor-kappa B ligand (RANKL) increase.  When 
RANKL expression is enhanced relative to its competitor osteoprotegrin (OPG), RANKL is 
available to bind RANK receptor on osteoclast precursor cells activating osteoclast formation 
and bone resorption9.  
 
Based on this model, it is abundantly clear that although the bacterial biofilm does not directly 
cause bone and tissue destruction, its presence is the primary etiology of plaque induced 
periodontitis.  Therefore, the first phase of treatment in periodontal disease is mechanical 
therapy, which aims to reduce bacterial biofilm present at the site of infection. This is 
accomplished by scaling and root planning with hand and ultrasonic instruments in an attempt to 
debride the teeth and soft tissue.  Studies have confirmed the efficacy scaling and root planing 
accompanied with improved oral hygiene, resulting in a shift away from disease and back to a 
healthy state10. Scaling and root planing however does have its limitations, namely the initial 
pocket depth, the anatomy of the tooth root surface and the number of roots present11,12.  
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Generally speaking, the deeper the probing the depth, the less likelihood of complete removal of 
plaque and calculus13. Furthermore, despite meticulous mechanical therapy, persistent bacteria 
can still remain due their ability to invade host cells, survive and replicate, and then serve as a 
reservoir for future re-infections14.  
 
Based on the infectious nature of periodontal disease, some clinicians have advocated the use of 
antibiotics as an adjunct to mechanical therapy in order to further decrease the bacterial load. 
Ideally targeting specific periodontal pathogens and not commensal species15.  A 2003 
systematic review analyzing the clinical benefits of antibiotics as both an adjunct to mechanical 
debridement and a sole therapy concluded that systemic antibiotics were uniformly beneficial in 
providing improvement in attachment loss when used as adjuncts to scaling and root planing; 
with borderline significance when used as stand-alone therapy. The clinical benefits of 
antibiotics however only surmounted to about 0.3mm to 0.4mm mean “gain” in attachment, 
indicating only a slight advantage over mechanical debridement with no antibiotics7. The results 
of that paper provide support for judicious application of antibiotics rather than routine use with 
periodontal therapy.  A 2004 position paper on systemic antibiotic use in periodontics published 
by the American Academy of Periodontics further supported this notion by concluding that 
systemic antibiotics is only appropriated for patients that do not respond to adequate mechanical 
therapy, manifest acute periodontal infections, as a prophylaxis for medically compromised 
patients and as an adjunct to both surgical and non-surgical therapy16. A recent study conducted 
on 400 patients with chronic periodontitis being treated in the United States revealed that 74.2% 
patients had at least one periodontal pathogen exhibit resistance to the therapeutic concentrations 
of antibiotics commonly used in clinical periodontal practice.  One or more periodontal 
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pathogens exhibited resistance to doxycycline in 220 (55.0%) patients, to amoxicillin in 173 
(43.3%) patients, to metronidazole in 121 (30.3%) patients, and to clindamycin in 106 (26.5%) 
patients. In addition, 60 (15.0%) of the study patients harbored subgingival test periodontal 
pathogens resistant in vitro to both amoxicillin and metronidazole17.  With the publication of 
these influential studies, it can be concluded that the risks of routinely prescribing broad 
spectrum antibiotics only used to treat periodontal pathogens heavily outweighs the benefits.   
 
Yet the subgingival bacterial biofilm remains an alluring target for the treatment of periodontal 
disease because of its influence in dysbiosis and the subsequent progression of disease.  This has 
led the periodontal community to seek the ideal antibiotic, one that could target only the 
periodontal pathogens and marginalize the chances of bacterial resistance.  In the field of 
medicine, amixicile is a promising novel antimicrobial that affects strict anaerobes by targeting 
the cofactors of essential enzymatic reactions necessary for metabolism.  It selectively targets the 
disease promoting bacteria by affecting pyruvate:ferredoxin oxidoreductase (PFOR) enzyme. 
PFOR catalyzes the conversion of pyruvate and Coenzyme A (CoA) to CO2 and Acetyl-CoA and 
is an important component of many metabolic pathways found in anaerobic bacteria and 
parasites. This pathway is highly conserved, and therefore resistance to Amixicile by mutation  is 
conceptually impossible18–20. In a mouse model, Amixicile was shown to have an inhibitory 
effect on Clostridium difficile infection, less systemic side effects, and reduced number of 
resistant bacteria when compared to vancomycin and fidaxomicin21. 
 
Amixicile was shown to be effective specifically against anaerobic bacteria, therefore it should 
also be effective against specific anaerobic bacteria present in periodontal disease. To test this 
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hypothesis, our lab examined the effects of amixicile on the growth of oral anaerobic pathogens 
associated with periodontal disease.  Amixicile was able to inhibit the growth of laboratory 
strains of P. gingivalis, P. intermedia and F. nulceatum.  This warranted further studies on 
multispecies broth cultures that contained equal amounts of P.gingivalis, P. intermedia, A. 
actinomycetemcomitans, F. nuleatum, T. forsythia and S. gordonii.  DNA was isolated and qPCR 
analysis has shown that amixicile inhibited the growth of PFOR-containing bacteria P. 
gingivalis, P. intermedia, F. nucleatum and T. forsythia.  The amount of inhibition was 
comparable to cultures treated with metronidazole, the current treatment of choice for anaerobic 
periodontal pathogens22.   
 
Our current study aimed to evaluate the efficacy of amixicile on a complex microbiome 
harvested from sulcus of healthy patients and the periodontal pocket of patients with severe 
chronic periodontitis.  Our hypothesis is that within the microbiome model, amixicile will 
selectively inhibit specific pathogens associated with periodontal disease and spare commensal 
bacteria. We hypothesize that Amixicile will selectively inhibit PFOR bacteria and have similar 
effects on select bacterial species when compared to Metronidazole.  
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MATERIALS AND METHODS 
 
Study Population 
All of the samples harvested in this study came from patients of record at VCU Graduate 
Periodontics Clinic. All participants of the study completed a comprehensive periodontal exam at 
the VCU Department of Periodontology, and received informed consent prior to plaque harvest. 
Our inclusion criteria for all participants was as follows: 
1. Adult patients (age 21+)  
2. Non-diabetics  
3. The patient cannot have taken antibiotics within the 6 months  
4. Patient has not received periodontal therapy in the 6 months  
5. Non-pregnant patients  
6. Non-smokers  
7. No patients who required premedication prophylaxis due to joint replacement  
8. No aggressive periodontitis   
The diagnosis of disease severity was based on full mouth periodontal charting and clinical 
attachment levels. Severe chronic periodontitis was defined as inflammation of the periodontium 
with attachment loss of 5mm or more in conjunction with radiographic bone loss.  Health was 
considered probing depth of 3mm or less with no clinical signs of inflammation. 
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Biofilm Sample Collection 
Bacterial samples were harvested from the pocket originating from the mesial of first molars. 
Local anesthesia was provided to all patients for comfort. All sites were air dried, and cotton roll 
isolation was used. Supra-gingival plaque was gently removed from the tooth, so that the free 
gingival margin was not disturbed. The sample was harvested sub-gingivally via a sterile curette 
and stored in 500 µl of SHI medium. Sample was immediately transported into anaerobic 
chamber and another 500 µl of SHI medium, was added to lower the oxygen level of the sample. 
Samples were incubated overnight in an artificial atmosphere (composed of 80% N, 10% H, and 
10% CO2) at 37 oC using a Coy anaerobic chamber (Ann Arbor, MI), and then aliquoted to 100 
µl and stored in -80 oC with 10% of glycerol.   Sample aliquots from ten patients were pooled 
together and aliquoted to 50 µl of each for the following study. 
 
Antimicrobial Treatment 
50 µl of pooled sample was added to 4 mL of BHI with 10% of filtered human serum (Valley 
Biomedical), then separated into four containers. One was centrifuged and the pellet was kept at 
-20 oC for DNA isolation as baseline. The others were incubated at 37 oC in the anaerobic 
chamber with or without antimicrobial treatment. The concentrations of amixicile and 
metronidazole (Sigma) used in this study are 25 µg/mL. Pellets from the overnight cultures were 
obtained for DNA preparation.  These steps were then repeated exactly for the healthy samples.  
As a result, there are four groups of samples for the diseased and four groups of samples for the 
healthy groups.  The “before group” (B) which is the sample bacteria harvested but never 
incubated in vitro.  The “control group” (C) which is the sample of bacteria harvested and then 
incubated for 24 hours in the anaerobic chamber.  The “metronidazole group” (MET) which is 
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the sample of bacteria harvested and then incubated in the presence of 5 µl/mL of metronidazole.  
The “amixicile group” (AMX) which is the sample of bacteria harvested and then incubated in 
the presence of 5 µl/mL of amixicile.   
 
 DNA isolation and qPCR 
Cell pellets were re-suspended in 50 mM EDTA containing 10 mg/mL lysozyme and 100 U/mL 
mutanolysin (Sigma) and incubated at 37°C for 1 hr. DNA was isolated using the Wizard 
Genomic DNA purification kit (Promega) according to manufacturer’s instructions. The DNA 
was then used to quantify the presence of bacterial species in the various samples using a 7500 
Fast Real-time PCR machine (Thermo-Fisher). Purified DNA (1 µL) and species-specific 
primers were added to Fast SYBR Green Mastermix (Thermo-Fisher) and run using standard 
cycle conditions: 95°C for 20 sec (1 cycle); 95°C for 3 sec, 60°C for 30 sec (40 cycles). The 
species-specific 16S rDNA primer sequences used in this study are shown in below. The cycle 
threshold (Ct) data were collected and then converted to absolute fold change.  This process was 
completed three individual times to provide triplicates results from the data.   
 
DNAseq library generation 
 
1µg of purified gDNA was fragmented by covaris S2 ultrasonicator following the settings for 
Whole-genome Resequencing. ThruPLEX DNA-seq Kit (Rubicon Genomics) was used for 
library preparation according to manufacturer’s instructions. Library samples were run on the 
Bioanalyzer to check the quantity and quality, then processed for next generation sequencing 
through Nucleic Acids Research Facilities in VCU.  
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16S rDNA primers 
Porphyromonas gingivalis (Pg) 
HmuY F: GTGGCGAAAGTGGTAAGGGA 
HmuY R: TCAGCACCACGAACGAAGAA 
Lactobacillus acidophilus (La) 
La F: 
GGATAGAGGTAGTAACTGGCCTTTATT 
La R: CAGTTTCCGATGCAGTTCCTCG 
Prevotella intermedia (Pi) 
Pi F: CCATCAGGTTATGCTGGGCA 
Pi R: GTTGCAGACCTCAGTCCGAA 
Aggregatibacter actinomycetemcomitans (Aa) 
Aa F: AGTCGGACGGTAGCAGGTAA 
Aa R: GCTTGGTAGGCCTTTACCCC 
Fusobacterium nucleatum (Fn) 
Fn F: CTGGCTCAGGATGAACGC 
Fn R: ATGGGACGCAAAGCTCTCTC 
Treponema denticola (Td) 
Td F: AGCATGCAAGTCGAACGGTA 
Td R: AACTAGCTAATGGGACGCGG 
Tannerella forsythia 
Tf F: AGGATGACTGCCCTATGGGT 
Tf R: AAGCGACAAACTTTCACCGC 
Veillonella atypical (Va) 
Va F: CGGCTACTGATCATCGCCTT 
Va R: ATCTTAGTGGCGAACGGGTG 
Streptococcus gordonii (Sg) 
Sg F: GCAATTGCACCACTACCAGA 
Sg R: TGCTCGGTCAGACTTTCGTC 
Streptococcus mutans (Sm) 
Sm F: GCACACCGTGTTTTCTTGAGTCG 
Sm R: CGGCTATGTATCGTCGCCTT 
Streptococcus anginosus (Sa) 
Sa F: GAGTGCTAGGTGTTGGGTCC 
Sa R: 
TGTTCCGAAGAAACTTCCTATCTCT 
16S universal F: 
AGAGTTTGATCCTGGCTCAG 
16S universal R: 
GCTGCCTCCCGTAGGAGT 
 
 
Statistical Analysis 
Each run used two antimicrobials (amixicile, and metronidazole—each in duplicate) with 16s 
targeted and 12 bacterial species targeted (Pg, Pi, Fn, La, Aa, Td, Tf, Va, Sa, Sm, and Sg). CT 
values were also measured before incubation on the 12+1 targets. The after incubation CT values 
were normalized by subtracting each 16s value difference with the non-controls. The corrected 
CT values were analyzed using a mixed-model ANOVA with the following factors: 
Antimicrobial treatment, bacterial species-a repeated, within-sample factor, and the 
Antimicrobial*Species interaction. The before incubation CT values (un-normalized) were also 
compared to the control values.   
  
 19 
 
 
RESULTS 
 
Plaque Harvest and Growth 
Before incubation samples (B) were compared to the Control samples (C). Figure 1 displays a 
comparison between (B) before and (C) Control. The lower the CT value, the more bacteria are 
present in the sample.  The diseased group (D sample) harvested from the chronic periodontitis 
patients and the healthy group (H sample) harvested from the healthy non chronic periodontitis 
patients.  PCR analysis was performed three times for the D samples and the H samples, creating 
triplicates.  Error! Reference source not found. shows the difference in CT values from the 
before groups (B) and the control groups (C) in both the diseased samples (D1-3) and healthy 
samples (H1-3).  This analysis shows an increase in nearly all of the bacteria tested, which is 
indicated by a decrease in the CT value.  Based on this data, the incubation methods employed 
were successful in culturing and growing the bacteria harvested from patients.   
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Figure 1. Control group: Comparison of Bacteria Before and After Incubation  
Figure 1 displays the comparison of CT values before incubation plaque samples harvested (B 
Group) in blue and the control samples incubated for 24 hours in the anaerobic chamber (C 
group) in red. The decrease in CT value corresponds to a greater quantity of bacteria in the 
sample. 
0
5
10
15
20
25
30
35
40
1
6
s
P
g P
i
F
n
L
a
A
a
T
d T
f
V
a
S
a
S
m S
g
1
6
s
P
g P
i
F
n
L
a
A
a
T
d T
f
V
a
S
a
S
m S
g
1
6
s
P
g P
i
F
n
L
a
A
a
T
d T
f
V
a
S
a
S
m S
g
1
6
s
P
g P
i
F
n
L
a
A
a
T
d T
f
V
a
S
a
S
m S
g
1
6
s
P
g P
i
F
n
L
a
A
a
T
d T
f
V
a
S
a
S
m S
g
1
6
s
P
g P
i
F
n
L
a
A
a
T
d T
f
V
a
S
a
S
m S
g
1D 1H 2D 2H 3D 3H
U
n
n
o
rm
a
liz
e
d
 
C
T
Before Control
  21 
 
Figure 2. Control: Difference in Bacteria Before and After Incubation 
Figure  2  is the difference in CT values of the B group and C group for each D and H 
sample.  This data shows that with the exception of Pg in the 2D group and Aa in the 
2D group, the incubation method utilized in this study resulted in successful growth of 
the bacteria harvested from patients.  
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Total Bacteria in Healthy Runs 
The three individual runs were analyzed as one combined experiment. This was accomplished by 
adding an additional factor to the ANOVA model: “H Combined” (1H, 2H, 3H). This permits 
each run to have a different mean level. Table 1 displays the corrected CT means compiled from 
the three individual qPCR runs. From Table 1 and  
Figure 2, within each bacterial species, there were differences in the relative abundance under 
the three antimicrobial conditions. High abundant species which is reflected by a low CT value 
were seen for: Pi, Fn, Va, Sa, Va, Sm and Ss. Whereas bacterial species Pg, La, Aa, Td, and Tf 
displayed a decreased abundance which is reflected by a higher CT value.  
 
From Table 1 and  
Figure 2 there were statistical significant differences for Pg (P=.001), Pi (P<.001), Va (P<.001), 
and Sm (P<.001). For the 3 treatment groups, there are 3 paired comparisons—2 with the control 
and 1 for amixicile vs metronidazole. For those with an overall difference, an individually 
identifiable difference is declared if the p-value for the comparison is less than 0.05/3—a 
correction for multiple comparisons. In the table, if the active antimicrobial is significantly 
different from the control, then the active antimicrobial is labeled with a “-c” and if amixicile is 
different than metronidazole then each antimicrobial is labeled with “-x”. From Table 1 and  
Figure 2 it demonstrates a difference from the control and amixicile in the following bacterial 
species: Pi, Va, and Sm. A difference was seen from the control and metronidazole in the 
following bacterial species: Pi, Va, and Sm. Lastly between amixicile and metronidazole, 
differences were observed for bacterial primers Pg and Sm
  23 
Table 1. Corrected CT mean estimates for the three healthy runs combined (H samples) 
Antimicrobials Estimate
Pg (P=.001) Control 38.18 37.39 38.98
Amixicile-x 39.08 38.28 39.87
Metronidazole-x 36.80 36.00 37.59
Pi (P<.001) Control 27.23 26.43 28.02
Amixicile-c 29.46 28.66 30.25
Metronidazole-c 29.10 28.31 29.90
Fn (P=.553) Control 27.01 26.21 27.80
Amixicile 26.79 26.00 27.58
Metronidazole 26.41 25.62 27.20
La (P=.008) Control 35.74 34.94 36.53
Amixicile-x 35.70 34.91 36.49
Metronidazole-cx 37.33 36.54 38.13
Aa (P=.048) Control 32.15 31.36 32.94
Amixicile 31.50 30.71 32.30
Metronidazole-c 30.73 29.93 31.52
Td (P=.041) Control 33.64 32.84 34.43
Amixicile 34.96 34.16 35.75
Metronidazole 33.74 32.95 34.54
Tf (P=.030) Control 33.11 32.32 33.91
Amixicile 31.87 31.07 32.66
Metronidazole-c 31.69 30.90 32.49
Va (P<.001) Control 14.67 13.88 15.46
Amixicile-c 21.79 21.00 22.59
Metronidazole-c 20.84 20.05 21.63
Sa (P=.744) Control 21.04 20.25 21.84
Amixicile 21.44 20.65 22.24
Metronidazole 21.36 20.57 22.15
Sm (P<.001) Control 15.21 14.41 16.00
Amixicile-cx 18.34 17.55 19.14
Metronidazole-cx 16.63 15.84 17.43
Sg (P=.022) Control 19.79 18.99 20.58
Amixicile-c 21.37 20.58 22.17
Metronidazole 20.84 20.05 21.64
95% CI
Corrected CT
Bacterial 
species
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Figure 3. Corrected CT mean estimates for the three healthy runs combined (H samples) 
Figure 3 includes the average CT values taken from the C, AMX and MET (microbiomes 
prepared on different days) each run in triplicate (n=9).  ANOVA analysis was performed and 
applied to compare the control group to amixicile, control group to metronidazole and lastly 
compare amixicile and metronidazole. A “c” represents a statistically significant difference from 
control and antimicrobial. An “x” represents a statistically significant difference from amixicile 
and metronidazole.
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The results for comparing each of the antimicrobials, separately within each bacterial species is 
shown in Appendix A Table 14 and these differences may be transformed into a fold-change by 
taking the differences with controls and exponentiating the difference. Exponentiating the 95% 
confidence intervals on the differences yields the 95% CI estimate for the fold estimate (and so, 
the CI’s are not symmetric around the fold estimate).Table 2 and Figure 4 display the fold 
changes observed for all of the H sample runs combined. Statistically significant reductions were 
seen for Pi (<.001), Va (<.001), and Sm (<.001). No statistically significant increases were seen 
for Pg, Fn, La, Aa, Td, Tf, Sa and Sg (P>.001).  A fold change decrease was observed for 
amixicile on Pi, Va and Sm but a fold change decrease for metronidazole was only observed for 
Va. 
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Table 2. Fold change for the three healthy runs combined (H samples) 
Antimicrobials Estimate
Pg Amixicile (P=.115) 0.539 0.247 1.173
Metronidazole (P=.017) 2.610 1.199 5.685
Pi Amixicile (P<.001) 0.213 0.098 0.465
Metronidazole (P=.002) 0.273 0.125 0.594
Fn Amixicile (P=.697) 1.162 0.533 2.530
Metronidazole (P=.287) 1.512 0.694 3.293
La Amixicile (P=.948) 1.025 0.471 2.233
Metronidazole (P=.007) 0.330 0.152 0.719
Aa Amixicile (P=.248) 1.567 0.720 3.413
Metronidazole (P=.015) 2.680 1.231 5.836
Td Amixicile (P=.023) 0.401 0.184 0.874
Metronidazole (P=.852) 0.931 0.427 2.027
Tf Amixicile (P=.031) 2.372 1.089 5.166
Metronidazole (P=.015) 2.673 1.227 5.821
Va Amixicile (P<.001) 0.007 0.003 0.016
Metronidazole (P<.001) 0.014 0.006 0.030
Sa Amixicile (P=.470) 0.757 0.347 1.647
Metronidazole (P=.567) 0.802 0.368 1.746
Sm Amixicile (P<.001) 0.114 0.052 0.248
Metronidazole (P=.015) 0.373 0.171 0.812
Sg Amixicile (P=.007) 0.333 0.153 0.725
Metronidazole (P=.064) 0.480 0.221 1.046
95% CI
FoldBacterial 
species
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Figure 4. Fold changes observed for the three healthy runs combined (H samples) 
Figure 4 represents the fold change in CT values taken from the AMX and MET 
(microbiomes prepared on different days) each run in triplicate.  A P Value <.001 
represented a statistical significant change in the numbers of bacteria from the control 
and antimicrobial treatment.
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Total Bacteria in Diseased Runs 
The three individual diseased samples (D samples) were also analyzed as one combined 
experiment. The same data processing and analysis were performed on the H samples data was 
also performed on the D samples data. The average corrected CT estimates are shown in  
 
 
 
Table 3 and Figure 5. Corrected CT mean estimates for the three diseased runs combined 
(D samples) 
 
. Similar trends were observed in regards to the abundance levels seen in the H samples, and 
certain bacteria were present in high abundance relative to others. Higher abundant species 
represented by a low control CT value included Pi, Fn, Va, Sa, Sg and Sm. Whereas a higher CT 
control value reflected lower abundant species and included Pg, La, Aa, Td and Tf.  
 
Statistical significant differences were observed for Pi (P<.001), Fn (P<.001), Va (<.001) and La 
(P<.001). Within the three treatment groups, there are 3 paired comparisons—2 with the control 
and 1 for amixicile vs metronidazole. From Table 2 it demonstrates a difference from the control 
and amxicile in the following bacterial species: Pi, Fn, Sg, Va, La, and Td. A difference was seen 
from the control and metronidazole in the following bacterial species: Pi, Fn, Va, La and Sm. 
Lastly between amixicile and metronidazole, a difference was observed for Td species.  
 
The results for comparing each of the antimicrobials, separately within each bacterial species is 
shown in Appendix A Table 24. And these differences may be transformed into a fold-change by 
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taking the differences with controls and exponentiating the difference. Exponentiating the 95% 
confidence intervals on the differences yields the 95% CI estimate for the fold estimate (and so, 
the CI’s are not symmetric around the fold estimate). Error! Reference source not found. and 
Error! Reference source not found. 
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Table 3. Corrected CT mean estimates for the three diseased runs combined (D samples) 
Antimicrobials Estimate
Pg (P<.001) Control 30.92 30.55 31.29
Amixicile-c 29.71 29.34 30.08
Metronidazole-c 29.59 29.23 29.96
Pi (P<.001) Control 17.95 17.58 18.32
Amixicile-cx 25.63 25.26 26.00
Metronidazole-cx 26.73 26.36 27.10
Fn (P<.001) Control 23.59 23.22 23.96
Amixicile-cx 24.66 24.30 25.03
Metronidazole-cx 25.37 25.00 25.73
La (P<.001) Control 28.27 27.90 28.63
Amixicile-c 27.04 26.67 27.40
Metronidazole-c 26.85 26.48 27.22
Aa (P=.029) Control 34.08 33.71 34.44
Amixicile-c 33.36 32.99 33.73
Metronidazole 33.77 33.40 34.14
Td (P=.088) Control 28.48 28.11 28.84
Amixicile 27.90 27.53 28.27
Metronidazole 28.27 27.90 28.64
Tf (P<.001) Control 26.80 26.43 27.17
Amixicile-x 27.17 26.80 27.54
Metronidazole-cx 28.09 27.72 28.45
Va (P<.001) Control 14.85 14.49 15.22
Amixicile-cx 23.42 23.05 23.79
Metronidazole-cx 25.02 24.66 25.39
Sa (P=.267) Control 15.81 15.44 16.18
Amixicile 15.42 15.05 15.79
Metronidazole 15.47 15.10 15.84
Sm (P=.314) Control 15.70 15.33 16.06
Amixicile 15.56 15.19 15.92
Metronidazole 15.95 15.58 16.31
Sg (P<.001) Control 18.07 17.70 18.43
Amixicile-cx 17.29 16.92 17.66
Metronidazole-x 18.46 18.10 18.83
95% CI
Corrected CT
Bacterial 
species
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Figure 5. Corrected CT mean estimates for the three diseased runs combined (D samples) 
 
Figure 5 includes the average CT values taken from the C, AMX and MET groups 
(microbiomes prepared on different days) each run in triplicate (n=9). ANOVA 
analysis was performed and applied to compare the control group to amixicile, control 
group to metronidazole and lastly compare amixicile and metronidazole. A “c” 
represents a statistically significant difference from control and antimicrobial. An “x” 
represents a statistically significant difference from amixicile and metronidazole.
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Table 4. Fold change for the three diseased runs combined (D samples) 
 
Antimicrobials Estimate
Pg Amixicile (P<.001) 2.311 1.611 3.313
Metronidazole (P<.001) 2.508 1.749 3.597
Pi Amixicile (P<.001) 0.005 0.003 0.007
Metronidazole (P<.001) 0.002 0.002 0.003
Fn Amixicile (P<.001) 0.475 0.331 0.681
Metronidazole (P<.001) 0.292 0.204 0.419
La Amixicile (P<.001) 2.345 1.636 3.362
Metronidazole (P<.001) 2.671 1.863 3.829
Aa Amixicile (P=.008) 1.645 1.147 2.358
Metronidazole (P=.237) 1.237 0.863 1.774
Td Amixicile (P=.031) 1.492 1.040 2.139
Metronidazole (P=.420) 1.155 0.806 1.656
Tf Amixicile (P=.160) 0.775 0.541 1.112
Metronidazole (P<.001) 0.411 0.287 0.589
Va Amixicile (P<.001) 0.003 0.002 0.004
Metronidazole (P<.001) 0.001 0.001 0.001
Sa Amixicile (P=.138) 1.309 0.913 1.877
Metronidazole (P=.193) 1.265 0.882 1.814
Sm Amixicile (P=.583) 1.103 0.769 1.582
Metronidazole (P=.336) 0.842 0.587 1.207
Sg Amixicile (P=.005) 1.713 1.195 2.456
Metronidazole (P=.128) 0.758 0.529 1.088
95% CI
FoldBacterial 
species
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Figure 6. Fold changes observed for the three diseased samples combined (D samples) 
Figure 6 represents the fold change in CT values taken from the AMX and MET 
(microbiomes prepared on different days) each run in triplicate. A P Value <.001 
represented a statistical significant change in the numbers of bacteria from the control 
and antimicrobial treatment.
0.001
0.010
0.100
1.000
10.000
A
m
ix
ic
ile
 (
P
<
.0
0
1
)
M
e
tr
o
n
id
a
z
o
le
 (
P
<
.0
0
1
)
A
m
ix
ic
ile
 (
P
<
.0
0
1
)
M
e
tr
o
n
id
a
z
o
le
 (
P
<
.0
0
1
)
A
m
ix
ic
ile
 (
P
<
.0
0
1
)
M
e
tr
o
n
id
a
z
o
le
 (
P
<
.0
0
1
)
A
m
ix
ic
ile
 (
P
<
.0
0
1
)
M
e
tr
o
n
id
a
z
o
le
 (
P
<
.0
0
1
)
A
m
ix
ic
ile
 (
P
=
.0
0
8
)
M
e
tr
o
n
id
a
z
o
le
 (
P
=
.2
3
7
)
A
m
ix
ic
ile
 (
P
=
.0
3
1
)
M
e
tr
o
n
id
a
z
o
le
 (
P
=
.4
2
0
)
A
m
ix
ic
ile
 (
P
=
.1
6
0
)
M
e
tr
o
n
id
a
z
o
le
 (
P
<
.0
0
1
)
A
m
ix
ic
ile
 (
P
<
.0
0
1
)
M
e
tr
o
n
id
a
z
o
le
 (
P
<
.0
0
1
)
A
m
ix
ic
ile
 (
P
=
.1
3
8
)
M
e
tr
o
n
id
a
z
o
le
 (
P
=
.1
9
3
)
A
m
ix
ic
ile
 (
P
=
.5
8
3
)
M
e
tr
o
n
id
a
z
o
le
 (
P
=
.3
3
6
)
A
m
ix
ic
ile
 (
P
=
.0
0
5
)
M
e
tr
o
n
id
a
z
o
le
 (
P
=
.1
2
8
)
Pg Pi Fn La Aa Td Tf Va Sa Sm Sg
F
o
ld
 C
h
a
n
g
e
D combined
  
34 
 
 
 
DISCUSSION 
Chronic periodontitis is a an inflammatory disease induced by a sub-gingival biofilm often 
associated with gram negative anaerobic bacteria such as Porphyromonas gingivalis, Tannerella 
forsythia and Treponema denticola7.  The sub-gingival biofilm enable bacteria to flourish in a 
layered ecosystem that involves adherence to a solid surface (the tooth), surrounded by microbial 
polysaccharides and protein matrix.  This complex eco-system provides numerous protective 
advantages to the bacteria including: nutrient availability and uptake, removal of potentially 
harmful metabolic products, evasion of the host immune system and ability to share genes 
particularly ones that provide resistance to antibiotics4.  Socransky identified six groups of oral 
bacterial species and grouped them according their spatial relationships which include; yellow, 
green, purple, orange and red complexes. These complexes represent a group of distinct bacterial 
species that tend to aggregate together and contribute to the collective survival of the complex 
within the micro-biofilm. Complexes green and purple act as early colonizers, and have the 
ability to attach directly to the tooth. Orange and red complexes tend to be associated with 
pathogenic bacteria that cause periodontal destruction7. 
 
Periodontitis is first managed with mechanical therapy aimed at reducing the overall quantity of 
bacteria and implementing better oral hygiene practices to the patient.  Numerous studies have 
showcased the benefits of mechanical therapy in the treatment of periodontal disease such as 
reduction in inflammation and bleeding in probing, along with decreases in probing depths, 
detoxification of root surfaces and clinical attachment gain 11,12,14,23. Despite its effectiveness, 
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mechanical therapy is unable to remove all pathogens associated with disease. The trend 
observed in clinical practice is that as disease severity increases the odds of effective removal 
decrease11,12.  Additionally bacterial re-contamination following debridement can take place in as 
little as 42 days, therefore strict maintenance schedules are required for all patients presenting 
with periodontal disease24,25. 
 
The undeniable microbial etiology of periodontal diseases provides the rationale for the use of 
antimicrobial agents in the treatment and resolution of both microbes and the inflammation they 
induce. A systematic review published in 2003, showed that systemic antibiotics when used as an 
adjunct to scaling and root planing was shown to be “uniformly beneficial” in providing 
improvement in attachment loss26. Certain antibiotics are considered “ideal” for periodontal 
infections based on their ability to target anaerobic bacteria, or ability to concentrate in the 
gingival fluid27. The primary drawback to systemic antibiotics is the well-documented problem 
of bacterial resistance. Meaning that once exposed, certain strains of bacteria are able to survive, 
and then pass their resistant genes onto the next generation. In a 2014 study, which sought to 
measure the antibiotic resistance in human chronic periodontitis microbiota, researchers found 
that "patients with chronic periodontitis frequently yielded sub gingival periodontal pathogen 
resistance to in vitro concentrations of antibiotics commonly (amoxicillin, clindamycin and 
metronidazole)  used in clinical periodontal practice17.”  
 
Amoxicillin is a medium spectrum bacteriolytic, -lactam antibiotic that targets susceptible gram 
positive and gram negative bacteria.  Amoxicillin inhibits the cross-linkage between the linear 
peptidoglycan polymer chains that make up a major component of the cell wall of gram-positive 
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and a minor component of the gram-negative bacteria.  In a double blinded, placebo controlled 
randomized clinical trial, Winkel et al  investigated the effects of conventional initial periodontal 
therapy followed by systemic amoxicillin and clavulanic acid in adult periodontitis  
patients in a double blinded, placebo-controlled randomized clinical trial. Patients received 10 
days of systemic antibiotic or placebo after completion of thorough initial periodontal therapy. 
Winkel et al concluded that in comparison to placebo, adjunctive amoxicillin plus clavulanic acid 
does not provide additional clinical and microbiological effects in the treatment of adult 
periodontitis patients. 12 months after therapy, there were no differences in plaque index, 
bleeding on probing, gingival index, probing depths or clinical attachment levels28.  Of the 400 
patients studied in the Rams et al investigation, 173 or 43.3% of the patients exhibited 
periodontal pathogens with resistance to amoxicillin17.   
 
Clindamycin is a broad spectrum bacteriostatic antibiotic that targets both aerobic and anaerobic 
bacteria via inhibition of protein synthesis.  Gordon et al evaluated the efficacy of clindamycin 
as an adjunct to conventional periodontal therapy in the treatment of patients who had previously 
been unsuccessfully treated with scaling, periodontal surgery and use of tetracycline.   At 12 and 
24 months in the group of 13 patients, the annual rate of active disease progression reduced 
10.7% to 0.5%.  Bleeding on probing reduced from 33% to 8% and gingival inflammation 
decreased from 36% to 1% in patients receiving clindamycin plus scaling compared to scaling 
alone.  This was accompanied by a reduction in probing depths along with microbial flora29,30.  
Although effective against anaerobes, the broad spectrum nature of clindamycin puts patients at 
risk for pseudomembranous colitis, which is accompanied by an overgrowth of Clostridium 
difficile which is inherently resistant to clindamycin.  This results in the production of toxins that 
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cause adverse effects such as diarrhea, colitis and toxic megacolon31,32.  Of the 400 patients 
studied in the Rams et al investigation, 106 or 26.5% of the patients exhibited periodontal 
pathogens with resistance to clindamycin17.  Due to the potential harm of adverse side effects and 
high rate of resistance, it is recommended that clindamycin be used with great caution. 
 
Metronidazole is a limited spectrum antibiotic compound of the nitroimidazole class, it inhibits 
nucleic acid synthesis by disrupting the DNA of microbial cells.  Considered a pro-drug, 
metronidazole is activated only in anaerobic cells, where partially reduced and begin to function 
as a bactericidal antibiotic33.  It is considered the gold standard, and has been shown to be 
effective in reducing the periodontal pathogens in moderate to severe chronic periodontal 
pockets, in particular as an adjunct to scaling and root planning34.  Loesche et al,  provided 
patients with metronidazole during initial therapy, and found that even after 6.4 years follow up 
time, patients receiving this adjunct therapy had less need for surgery.  Despite its ability to 
target strict anaerobes associated with disease, Metronidazole has several harmful side effects 
including: nausea, gastrointestinal disturbances, disulfram reaction, and neuropathies34. It has 
been linked to outbreaks in Stevens-Johnson syndrome as well as sudden death due to ethanol 
interactions35–37.  Of the 400 patients studied in the Rams et al investigation, 121 or 30.3% of the 
patients exhibited periodontal pathogens with resistance to metronidazole17.  The potential for 
harmful side effects is very high with the use of metronidazole, and as a result its popularity 
among prescribers has been declining.   
 
The American Academy of Periodontology’s position paper on the use of systemic antibiotics in 
periodontics states that the prime candidates for systemic antibiotic therapy are patients who 
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exhibit continuing loss of periodontal attachment despite diligent conventional mechanical 
periodontal therapy. They advocate the conservative use of systemic antibiotics with particular 
attention to be paid to the patient, the pathogenic microbiota and the drug administered16.  Based 
on these recommendations, it may be necessary to seek an antimicrobial agent, which can 
specifically target “keystone” pathogens, avoid bacterial resistance and all the while not harm the 
host.  
 
Amixicile is newly discovered potent inhibitor of Clostridium difficile, a gram-positive obligate 
anaerobe that is associated with pseudomembranous colitis in patients receiving long-term 
broad-spectrum antibiotics. Its mechanism is through the inhibition of pyruvate:ferredoxin 
oxidoreductase, a critical enzyme involved in the vitamin synthesis pathway shared by many 
anaerobes. Because this pathway is highly conserved and essential, resistance to this novel 
therapeutic agent is not compatible with life. As a result, amixicile is showing great promise to 
patients suffering from pseudomembranous colitis and are unable to take any other antibiotics21.  
 
Like metronidazole, amixicile targets specific anaerobic bacteria, however it differs in it 
mechanism of action.  Amixicile targets and inhibits the pyruvate:ferredoxin oxidoreductase 
(PFOR), an essential enzyme for central metabolism.  PFOR catalyzes the conversion of 
pyruvate and Coenzyme A (CoA) to CO2 and Acetyl-CoA.  Once Acetly-CoA has been 
produced, it is then reduced to Acetate producing ATP in the process.  Amixicile targets the  
thiamine pyrophosphate (TPP) vitamin cofactor of PFOR by outcompeting the substrate pyruvate 
by nearly 2 orders of magnitude19,38.  Animal research models have evaluated the effects when 
administering systemic Amixicile in the treatment of a Clostriudum difficile infection and 
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compared it to traditional Vancomycin. Researchers found Amixicile was efficacious in 
eradicating the disease, but also displayed low toxicity, excellent drug metabolism, and an 
absence of mutation-based drug resistance21.  They concluded that Amixicile could be a potential 
new drug to be used in infections caused by PFOR-expressing bacteria.  P. gingivalis, P. 
intermedia, F. nucleatum and T. forsythia area all periodontal pathogens that express the PFOR 
enzyme, and are therefore novel targets to amixicile.   
 
Lewis et al, in a 2017 publication found that amixicile was effective on the growth of oral 
anaerobic pathogens associated with periodontal disease.  Amixicile showed a minimum 
inhibitory concentration of 1g/mL to laboratory strains of P. gingivalis, F. nulceatum and T. 
forsythia.  A higher dose of 5 μg/mL, was required to inhibit growth of P. intermedia.  
Amixicile was then tested on multispecies broth cultures that contained equal amounts of 
P.gingivalis, P. intermedia, A. actinomycetemcomitans, F. nuleatum, T. forsythia and S. 
gordonii.  DNA was isolated and qPCR analysis and amixicile inhibited the growth of PFOR-
containing bacteria P. gingivalis, P. intermedia, F. nucleatum and T. forsythia.  Moreover, the 
inhibition measured was comparable to cultures treated with metronidazole, the current treatment 
of choice for anaerobic periodontal pathogens22.   
 
Our study aimed to evaluate how an oral microbiome cultured from patients with periodontal 
disease and would respond to amixicile compared to healthy samples. To our knowledge this is 
the first study to investigate the effects of amixicile on a microbiome collected from human 
subjects. Amixicile testing on a microbiome sample cultured from patients with severe chronic 
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periodontal disease will provide more clinically relevant results compared to single species 
cultures previously tested.   
 
Our hypothesis is that amixicile will selectively inhibit PFOR utilizing anaerobic bacteria, and 
reduce their prevalence in the biofilm.  Secondly, we hypothesized that when compared to 
metronidazole, amixicile would act with similar efficacy in reducing the quantities of anaerobic 
bacteria.  We found that in the biofilm cultured from patients with severe chronic periodontitis, 
amixicile treatment, exhibited a statistical significant (P<.001) reduction in: P. intermedia,  F. 
nucleatum  and Veillonella atypical. All of these bacterial species utilize the PFOR pathway. 
When the data was evaluated to determine fold changes that occurred in the given bacterial 
species, both Amixicile and Metronidazole displayed a statistically significant (P<.001) decrease 
in the relative quantities of P. intermedia,  F. nucleatum and Veillonella atypical.   
 
The data supports the notion that amixicile targets specific anaerobic bacteria within an oral 
microbiome and performs with a similar degree of efficacy to metronidazole. All of the species 
that were affected have been implicated in the development and progression of periodontal 
disease7. Prevotella intermedia is a gram negative obligate anaerobe, associated with gingivitis, 
pregnancy gingivitis, periodontitis, acute necrotizing ulcerative gingivitis as well as dental 
abscesses39.  Fusobacterium nucleatum is a microbe associated with initiation of the microbial 
shift from a primarily gram + to gram – biofilm8.  This microbial shift is crucial in the 
development of periodontal disease, and the clinical attachment loss that follows. In vitro 
analysis has confirmed that F. nucleatum coaggregates with all of the following bacteria: P. 
gingivalis, Treponema denticola, A. actinomycetemcomitans, P. intermedia, Eubacterium 
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species, Selenomonas species and Actinomyces species40. In theory, if F.nucleatum could be 
targeted at an earlier stage, it could prevent the transition for a gram + to gram – micro-biofilm. 
This could potentially reduce the harmful effects the micro-biofilm causes in periodontal disease. 
Veillonella species have shown the ability to co-aggregate with other bacterial strains, and could 
provide an importance role in the initiation of bacterial colonization and biofilm formation41.   
 
When plaque samples from healthy patients were incubated in the presence of amixicile there 
was a statistically significant reduction (P<.001) for P. intermedia, Veillonella atypical and 
Streptococcus mutans.  When the data was evaluated to determine fold changes that occurred in 
the given bacterial species, both amixicile and metronidazole displayed a statistically significant 
(P<.001) decrease in the relative quantities of P. intermedia, Veillonella atypical and 
Streptococcus mutans for amixicile, while metronidazole displayed reductions only in P. 
intermedia and Veillonella atypical 
 
The results from this study provide support for additional research to be performed regarding the 
use of amixicile as a potential new antimicrobial in the treatment of periodontal disease. While 
this study is only in vitro, it demonstrates that amixicile targets strict anaerobes and reduces their 
quantity in samples derived from biofilms. While antibiotics have forever changed the practice of 
medicine, the issues with increasing drug resistance cannot be ignored. Within oral biofilms, 
resistance to amoxicillin, clindamycin, tetracycline, and metronidazole has been reported at 
surprisingly high rates17.  Amixicile targets a highly conserved pathway within anaerobes, 
therefore drug resistance as the result of mutation is conceptually impossible.  
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As the Academy of Periodontology outlines, antibiotic therapy needs to be considered for 
patients presenting with severe disease.  Ideally, thorough mechanical debridement should be 
performed with subsequent re-evaluation.  If inflammation persists even after mechanical 
therapy, then microbiological testing can be performed to determine the types of bacteria present. 
Sites with bleeding and deep probing depths, have been associated with specific periodontal 
pathogens including P.gingivalis, A. actinomycetemcomitans, and Fusobacterium species. As 
most bacteria associated with severe periodontal disease belong to anaerobic phyla, treatment 
with amixicile could provide additional benefits to patients and possibly reduce the need for 
surgical therapy in the future. 
 
Limitations to this research include a lack of effect seen with P.gingivalis.  P.gingivalis did not 
respond to either Amixicile or Metronidazole treatment. P.gingivalis has been regarded as a 
“keystone pathogen” and its presence has been linked with  active disease in periodontal 
pockets3. Ideally Amixicile and Metronidazole should both have an effect on P.gingivalis 
because P.gingivalis is a gram negative anaerobe. However little change was observed from the 
control and the antimicrobial treatment groups. Multiple factors could explain this finding, 
P.gingivalis is a difficult anaerobe to grow in laboratory conditions. It grows more slowly than 
other species within a biofilm, therefore after DNA isolation was performed the higher CT 
values would indicate a lower overall quantity of DNA.  It is likely that the P. gingivalis 
collected from patients has enough genetic variety that the traditional primers used for DNA 
detection would not accurately measure its presence.   
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Future research involving amixicile should focus on the effects it would have on periodontal 
disease, and other anaerobic infections in animal models. The systemic side effects, optimal 
dosing, and overall effect on periodontal disease remain to be determined with future research. 
Ultimately randomized clinical trials in human subjects would be needed in order to allow 
amixicile to be FDA approved in the treatment of periodontal disease, and possibly other 
diseases that are the result of anaerobic dominated infections.  
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CONCLUSIONS 
 
Amixicile is a promising new antimicrobial in the treatment of anaerobic bacterial infections. 
The effect of amixicile and metronidazole was dependent on the bacteria being analyzed. 
amixicile and metronidazole had an effect on PFOR-containing bacteria, specifically changes 
were seen for P. intermedia,  F. nucleatum  and Veillonella atypical. When comparing amixicile 
to metronidazole, amixicile performed with similar efficacy with the largest effect seen for 
PFOR bacteria. The data supports the notion that amixicile targets specific anaerobic bacteria 
within an oral micro-biofilm and performs with a similar degree of efficacy to metronidazole. 
Such a specific, non-toxic and bioavailable antimicrobial would be highly desirable for the 
treatment of periodontal disease. 
 
The authors confirm that there are no known conflicts of interest associated with this publication 
and there has been no significant financial support for this work that could have influenced its 
outcome. 
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Appendices 
Table 5. Corrected CT mean estimates for Set 1H 
Antimicrobials Estimate
Pg (P=.153) Control 38.23 37.26 39.20
Amixicile 39.57 38.60 40.55
Metronidazole 38.80 37.83 39.78
Pi (P<.001) Control 27.36 26.39 28.33
Amixicile-c 30.37 29.40 31.34
Metronidazole-c 30.14 29.16 31.11
Fn (P=.384) Control 27.89 26.92 28.86
Amixicile 27.77 26.80 28.74
Metronidazole 27.02 26.04 27.99
La (P<.001) Control 35.54 34.57 36.51
Amixicile-x 35.87 34.90 36.84
Metronidazole-cx 39.97 38.99 40.94
Aa (P=.033) Control 33.52 32.55 34.50
Amixicile 31.93 30.96 32.91
Metronidazole 31.88 30.91 32.85
Td (P=.798) Control 34.56 33.59 35.54
Amixicile 34.93 33.96 35.90
Metronidazole 34.98 34.01 35.95
Tf (P=.052) Control 34.09 33.12 35.06
Amixicile 32.93 31.95 33.90
Metronidazole 32.41 31.44 33.38
Va (P<.001) Control 14.92 13.95 15.89
Amixicile-c 21.55 20.57 22.52
Metronidazole-c 20.06 19.08 21.03
Sa (P<.001) Control 20.33 19.36 21.31
Amixicile-cx 23.34 22.37 24.31
Metronidazole-x 20.84 19.87 21.81
Sm (P<.001)Control 15.39 14.42 16.36
Amixicile-cx 19.51 18.54 20.48
Metronidazole-x 16.06 15.08 17.03
Sg (P=.005) Control 20.30 19.32 21.27
Amixicile-cx 22.52 21.55 23.49
Metronidazole-x 20.67 19.70 21.64
95% CI
Corrected CTBacterial 
species
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Least-squares means estimates from ANOVA analysis are shown. The analysis was applied to 
compare the control group to Amixicile, control group to Metronidazole and lastly compare 
Amixicile and Metronidazole. A “c” represents a statistically significant difference from control 
and antimicrobial. An “x” represents a statistically significant difference between Amxicile and 
Metronidazole. 
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Figure 7. Corrected CT mean estimates for Set 1H (95% CIs) 
Figure 7 represents the average CT values taken of Set 1H. ANOVA analysis was performed and 
applied to compare the control group to Amixicile, control group to Metronidazole and lastly 
compare Amixicile and Metronidazole. A “c” represents a statistically significant difference 
from control and antimicrobial. An “x” represents a statistically significant difference between 
Amxicile and Metronidazole. 
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Table 6. Differences in the Corrected CT mean estimates for Set 1H 
 
Compare Estimate
Pg CvA (P=.055) -1.342 -2.717 0.032
CvM (P=.401) -0.573 -1.947 0.801
AvM (P=.262) 0.769 -0.605 2.144
Pi CvA (P<.001) -3.011 -4.386 -1.637
CvM (P<.001) -2.776 -4.150 -1.401
AvM (P=.729) 0.236 -1.139 1.610
Fn CvA (P=.865) 0.115 -1.259 1.490
CvM (P=.205) 0.871 -0.503 2.246
AvM (P=.270) 0.756 -0.618 2.130
La CvA (P=.629) -0.328 -1.703 1.046
CvM (P<.001) -4.428 -5.802 -3.053
AvM (P<.001) -4.100 -5.474 -2.725
Aa CvA (P=.025) 1.589 0.215 2.963
CvM (P=.021) 1.641 0.267 3.016
AvM (P=.939) 0.052 -1.322 1.427
Td CvA (P=.590) -0.366 -1.741 1.008
CvM (P=.543) -0.414 -1.789 0.960
AvM (P=.944) -0.048 -1.422 1.326
Tf CvA (P=.095) 1.161 -0.213 2.535
CvM (P=.018) 1.678 0.304 3.053
AvM (P=.448) 0.517 -0.857 1.891
Va CvA (P<.001) -6.626 -8.000 -5.252
CvM (P<.001) -5.136 -6.510 -3.761
AvM (P=.035) 1.490 0.116 2.865
Sa CvA (P<.001) -3.004 -4.379 -1.630
CvM (P=.457) -0.507 -1.881 0.867
AvM (P<.001) 2.497 1.123 3.872
Sm CvA (P<.001) -4.118 -5.492 -2.744
CvM (P=.331) -0.666 -2.040 0.709
AvM (P<.001) 3.452 2.078 4.827
Sg CvA (P=.002) -2.227 -3.601 -0.852
CvM (P=.583) -0.373 -1.748 1.001
AvM (P=.010) 1.854 0.479 3.228
95% CI
Corrected CTBacterial 
species
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Figure 8. Differences in the Corrected CT mean estimates for Set 1H (95% CIs) 
Figure 10 represents the differences in corrected CT mean estimates from the original CT values 
after standardization with 16s primer for Set 1H. ANOVA analysis was performed and applied to 
compare the control group to Amixicile, control group to Metronidazole and lastly compare 
Amixicile and Metronidazole. A “c” represents a statistically significant difference from control 
and antimicrobial. An “x” represents a statistically significant difference between Amixicile and 
Metronidazole. 
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Table 7. Fold Estimates for Set 1H 
Antimicrobials Estimate
Pg Amixicile (P=.055) 0.394 0.152 1.023
Metronidazole (P=.401) 0.672 0.259 1.743
Pi Amixicile (P<.001) 0.124 0.048 0.322
Metronidazole (P<.001) 0.146 0.056 0.379
Fn Amixicile (P=.865) 1.083 0.418 2.808
Metronidazole (P=.205) 1.829 0.706 4.742
La Amixicile (P=.629) 0.797 0.307 2.065
Metronidazole (P<.001) 0.046 0.018 0.120
Aa Amixicile (P=.025) 3.009 1.160 7.800
Metronidazole (P=.021) 3.120 1.203 8.088
Td Amixicile (P=.590) 0.776 0.299 2.011
Metronidazole (P=.543) 0.750 0.289 1.945
Tf Amixicile (P=.095) 2.236 0.863 5.798
Metronidazole (P=.018) 3.200 1.234 8.297
Va Amixicile (P<.001) 0.010 0.004 0.026
Metronidazole (P<.001) 0.028 0.011 0.074
Sa Amixicile (P<.001) 0.125 0.048 0.323
Metronidazole (P=.457) 0.704 0.271 1.824
Sm Amixicile (P<.001) 0.058 0.022 0.149
Metronidazole (P=.331) 0.630 0.243 1.634
Sg Amixicile (P=.002) 0.214 0.082 0.554
Metronidazole (P=.583) 0.772 0.298 2.002
95% CI
FoldBacterial 
species
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Figure 9. Fold Estimates for Set 1H (95% CIs) 
Figure 11 represents the fold change observed for Set 1H for bacterial species after treatment of 
either Amixicile or Metronidazole. A P Value <.001 represented a statistically significant change 
in the numbers of bacteria from the control and antimicrobial treatment. 
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Table 8. Corrected CT mean estimates for Set 2 
 
Antimicrobials Estimate
Pg (P=.006) Control 38.00 36.80 39.20
Amixicile-x 38.38 37.18 39.58
Metronidazole-cx 35.70 34.50 36.91
Pi (P=.316) Control 27.95 26.75 29.16
Amixicile 28.67 27.47 29.87
Metronidazole 29.24 28.04 30.44
Fn (P=.346) Control 27.37 26.17 28.57
Amixicile 26.15 24.94 27.35
Metronidazole 26.88 25.68 28.08
La (P=.081) Control 35.07 33.87 36.27
Amixicile 35.54 34.34 36.74
Metronidazole 36.94 35.74 38.14
Aa (P=.313) Control 31.69 30.49 32.89
Amixicile 31.09 29.89 32.30
Metronidazole 30.40 29.20 31.60
Td (P=.220) Control 33.24 32.04 34.45
Amixicile 34.65 33.45 35.85
Metronidazole 33.53 32.32 34.73
Tf (P=.016) Control 32.78 31.58 33.99
Amixicile-c 30.33 29.13 31.53
Metronidazole 32.19 30.99 33.39
Va (P<.001) Control 14.50 13.29 15.70
Amixicile-c 22.64 21.43 23.84
Metronidazole-c 22.07 20.87 23.27
Sa (P=.033) Control 22.19 20.99 23.39
Amixicile-x 20.67 19.47 21.87
Metronidazole-x 22.93 21.72 24.13
Sm (P<.001)Control 15.36 14.15 16.56
Amixicile-c 19.25 18.05 20.45
Metronidazole-c 17.49 16.29 18.70
Sg (P=.067) Control 19.65 18.45 20.85
Amixicile 21.42 20.21 22.62
Metronidazole 21.39 20.19 22.59
95% CI
Corrected CTBacterial 
species
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Figure 10. Corrected CT mean estimates for Set 2H (95% CIs) 
Figure 12 represents the average CT values taken of Set 2H. ANOVA analysis was performed 
and applied to compare the control group to Amixicile, control group to Metronidazole and lastly 
compare Amixicile and Metronidazole. A “c” represents a statistically significant difference 
from control and antimicrobial. An “x” represents a statistically significant difference between 
Amxicile and Metronidazole. 
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Table 9. Differences in the Corrected CT mean estimates for Set 2H 
 
Compare Estimate
Pg CvA (P=.650) -0.381 -2.080 1.318
CvM (P=.010) 2.296 0.597 3.995
AvM (P=.003) 2.677 0.977 4.376
Pi CvA (P=.397) -0.715 -2.414 0.984
CvM (P=.133) -1.285 -2.985 0.414
AvM (P=.498) -0.570 -2.270 1.129
Fn CvA (P=.151) 1.226 -0.474 2.925
CvM (P=.558) 0.493 -1.206 2.192
AvM (P=.385) -0.733 -2.432 0.966
La CvA (P=.576) -0.471 -2.170 1.229
CvM (P=.032) -1.872 -3.572 -0.173
AvM (P=.102) -1.402 -3.101 0.298
Aa CvA (P=.481) 0.594 -1.105 2.293
CvM (P=.131) 1.291 -0.408 2.991
AvM (P=.409) 0.697 -1.002 2.397
Td CvA (P=.102) -1.404 -3.104 0.295
CvM (P=.738) -0.281 -1.980 1.418
AvM (P=.187) 1.123 -0.576 2.823
Tf CvA (P=.006) 2.451 0.752 4.150
CvM (P=.481) 0.593 -1.106 2.293
AvM (P=.033) -1.858 -3.557 -0.158
Va CvA (P<.001) -8.140 -9.839 -6.441
CvM (P<.001) -7.572 -9.271 -5.873
AvM (P=.500) 0.568 -1.131 2.267
Sa CvA (P=.078) 1.520 -0.179 3.219
CvM (P=.385) -0.733 -2.432 0.966
AvM (P=.011) -2.253 -3.952 -0.553
Sm CvA (P<.001) -3.894 -5.594 -2.195
CvM (P=.015) -2.138 -3.838 -0.439
AvM (P=.043) 1.756 0.057 3.455
Sg CvA (P=.042) -1.766 -3.465 -0.067
CvM (P=.045) -1.740 -3.439 -0.040
AvM (P=.975) 0.026 -1.673 1.726
95% CI
Corrected CTBacterial 
species
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Figure 11. Differences in the Corrected CT mean estimates for Set 2H (95% CIs) 
Figure 13 represents the differences in corrected CT mean estimates from the original CT values 
after standardization with 16s primer for Set 2H. ANOVA analysis was performed and applied to 
compare the control group to Amixicile, control group to Metronidazole and lastly compare 
Amixicile and Metronidazole. A “c” represents a statistically significant difference from control 
and antimicrobial. An “x” represents a statistically significant difference from Amixicile and 
Metronidazole.
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Table 10. Fold Estimates for Set 2H 
Antimicrobials Estimate
Pg Amixicile (P=.650) 0.768 0.237 2.494
Metronidazole (P=.010) 4.910 1.512 15.945
Pi Amixicile (P=.397) 0.609 0.188 1.978
Metronidazole (P=.133) 0.410 0.126 1.332
Fn Amixicile (P=.151) 2.339 0.720 7.594
Metronidazole (P=.558) 1.407 0.433 4.570
La Amixicile (P=.576) 0.722 0.222 2.343
Metronidazole (P=.032) 0.273 0.084 0.887
Aa Amixicile (P=.481) 1.509 0.465 4.902
Metronidazole (P=.131) 2.448 0.754 7.949
Td Amixicile (P=.102) 0.378 0.116 1.227
Metronidazole (P=.738) 0.823 0.253 2.673
Tf Amixicile (P=.006) 5.468 1.684 17.756
Metronidazole (P=.481) 1.509 0.465 4.899
Va Amixicile (P<.001) 0.004 0.001 0.012
Metronidazole (P<.001) 0.005 0.002 0.017
Sa Amixicile (P=.078) 2.868 0.883 9.313
Metronidazole (P=.385) 0.602 0.185 1.954
Sm Amixicile (P<.001) 0.067 0.021 0.218
Metronidazole (P=.015) 0.227 0.070 0.738
Sg Amixicile (P=.042) 0.294 0.091 0.955
Metronidazole (P=.045) 0.299 0.092 0.972
95% CI
FoldBacteria
l 
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Figure 12. Fold Estimates for Set 2H (95% CIs) 
Figure 14 represents the fold change observed for Set 2H for bacterial species after treatment of 
either Amixicile or Metronidazole. A P Value <.001 represented a statistical significant change 
in the numbers of bacteria from the control and antimicrobial treatment. 
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Table 11. Corrected CT mean estimates for Set 3H 
 
Antimicrobials Estimate
Pg (P<.001) Control 38.32 37.30 39.33
Amixicile-x 39.27 38.26 40.29
Metronidazole-cx 35.89 34.87 36.90
Pi (P<.001) Control 26.37 25.36 27.39
Amixicile-c 29.33 28.32 30.35
Metronidazole 27.94 26.92 28.95
Fn (P=.290) Control 25.76 24.75 26.78
Amixicile 26.45 25.44 27.47
Metronidazole 25.34 24.32 26.35
La (P=.114) Control 36.60 35.59 37.61
Amixicile 35.69 34.68 36.71
Metronidazole 35.09 34.08 36.11
Aa (P=.070) Control 31.24 30.22 32.25
Amixicile 31.48 30.46 32.49
Metronidazole 29.90 28.89 30.92
Td (P=.002) Control 33.11 32.09 34.12
Amixicile-cx 35.29 34.27 36.30
Metronidazole-x 32.72 31.71 33.74
Tf (P=.013) Control 32.47 31.45 33.48
Amixicile-x 32.34 31.33 33.35
Metronidazole-cx 30.48 29.47 31.50
Va (P<.001) Control 14.59 13.58 15.61
Amixicile-c 21.20 20.18 22.21
Metronidazole-c 20.39 19.38 21.41
Sa (P=.899) Control 20.60 19.59 21.61
Amixicile 20.32 19.31 21.34
Metronidazole 20.32 19.30 21.33
Sm (P=.079)Control 14.88 13.87 15.90
Amixicile 16.28 15.26 17.29
Metronidazole 16.34 15.33 17.36
Sg (P=.310) Control 19.41 18.39 20.42
Amixicile 20.18 19.16 21.19
Metronidazole 20.47 19.46 21.49
95% CI
Corrected CTBacterial 
species
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Figure 13. Corrected CT mean estimates for Set 3H (95% CIs) 
Figure 15 represents the average CT values taken of Set 3H. ANOVA analysis was performed 
and applied to compare the control group to Amixicile, control group to Metronidazole and lastly 
compare Amixicile and Metronidazole. A “c” represents a statistically significant difference 
from control and antimicrobial. An “x” represents a statistically significant difference from 
Amxicile and Metronidazole. 
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Table 12. Differences in the Corrected CT mean estimates for Set 3H 
 
Compare Estimate
Pg CvA (P=.184) -0.955 -2.389 0.479
CvM (P=.002) 2.430 0.995 3.864
AvM (P<.001) 3.385 1.951 4.819
Pi CvA (P<.001) -2.961 -4.395 -1.526
CvM (P=.034) -1.564 -2.999 -0.130
AvM (P=.056) 1.396 -0.038 2.831
Fn CvA (P=.332) -0.693 -2.127 0.742
CvM (P=.549) 0.425 -1.009 1.860
AvM (P=.122) 1.118 -0.316 2.552
La CvA (P=.207) 0.907 -0.528 2.341
CvM (P=.040) 1.507 0.073 2.941
AvM (P=.400) 0.600 -0.834 2.034
Aa CvA (P=.737) -0.238 -1.672 1.196
CvM (P=.067) 1.334 -0.100 2.768
AvM (P=.033) 1.572 0.138 3.006
Td CvA (P=.004) -2.182 -3.617 -0.748
CvM (P=.588) 0.385 -1.049 1.819
AvM (P<.001) 2.567 1.133 4.002
Tf CvA (P=.858) 0.127 -1.308 1.561
CvM (P=.008) 1.984 0.549 3.418
AvM (P=.013) 1.857 0.423 3.292
Va CvA (P<.001) -6.606 -8.040 -5.172
CvM (P<.001) -5.802 -7.237 -4.368
AvM (P=.261) 0.804 -0.631 2.238
Sa CvA (P=.696) 0.277 -1.158 1.711
CvM (P=.689) 0.284 -1.150 1.718
AvM (P=.992) 0.007 -1.427 1.442
Sm CvA (P=.056) -1.396 -2.830 0.039
CvM (P=.046) -1.463 -2.898 -0.029
AvM (P=.924) -0.068 -1.502 1.366
Sg CvA (P=.284) -0.767 -2.201 0.668
CvM (P=.141) -1.062 -2.496 0.372
AvM (P=.677) -0.295 -1.730 1.139
95% CI
Corrected CTBacterial 
species
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Figure 14. Differences in the Corrected CT mean estimates for Set 3H (95% CIs) 
Figure 16 represents the differences in corrected CT mean estimates from the original CT values 
after standardization with 16s primer for Set 3H. ANOVA analysis was performed and applied to 
compare the control group to Amixicile, control group to Metronidazole and lastly compare 
Amixicile and Metronidazole. A “c” represents a statistically significant difference from control 
and antimicrobial. An “x” represents a statistically significant difference from Amixicile and 
Metronidazole.
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Table 13. Fold Estimates for Set 3H 
Antimicrobials Estimate
Pg Amixicile (P=.184) 0.516 0.191 1.394
Metronidazole (P=.002) 5.388 1.994 14.563
Pi Amixicile (P<.001) 0.128 0.048 0.347
Metronidazole (P=.034) 0.338 0.125 0.914
Fn Amixicile (P=.332) 0.619 0.229 1.672
Metronidazole (P=.549) 1.343 0.497 3.629
La Amixicile (P=.207) 1.875 0.694 5.067
Metronidazole (P=.040) 2.842 1.052 7.681
Aa Amixicile (P=.737) 0.848 0.314 2.292
Metronidazole (P=.067) 2.521 0.933 6.813
Td Amixicile (P=.004) 0.220 0.082 0.595
Metronidazole (P=.588) 1.306 0.483 3.529
Tf Amixicile (P=.858) 1.092 0.404 2.950
Metronidazole (P=.008) 3.955 1.464 10.690
Va Amixicile (P<.001) 0.010 0.004 0.028
Metronidazole (P<.001) 0.018 0.007 0.048
Sa Amixicile (P=.696) 1.212 0.448 3.274
Metronidazole (P=.689) 1.218 0.451 3.291
Sm Amixicile (P=.056) 0.380 0.141 1.027
Metronidazole (P=.046) 0.363 0.134 0.980
Sg Amixicile (P=.284) 0.588 0.217 1.589
Metronidazole (P=.141) 0.479 0.177 1.295
95% CI
FoldBacterial 
species
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Figure 15. Fold Estimates for Set 3H (95% CIs) 
Figure 17 represents the fold change observed for Set 3H for bacterial species after treatment of 
either Amixicile or Metronidazole. A P Value <.001 represented a statistical significant change 
in the numbers of bacteria from the control and antimicrobial treatment. 
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Table 14. Differences in the Corrected CT mean estimates for three H Sets 
Compare Estimate
Pg CvA (P=.115) -0.893 -2.015 0.230
CvM (P=.017) 1.384 0.261 2.507
AvM (P<.001) 2.277 1.154 3.400
Pi CvA (P<.001) -2.229 -3.352 -1.106
CvM (P=.002) -1.875 -2.998 -0.752
AvM (P=.525) 0.354 -0.769 1.477
Fn CvA (P=.697) 0.216 -0.907 1.339
CvM (P=.287) 0.596 -0.526 1.719
AvM (P=.494) 0.380 -0.742 1.503
La CvA (P=.948) 0.036 -1.087 1.159
CvM (P=.007) -1.598 -2.721 -0.475
AvM (P=.006) -1.634 -2.757 -0.511
Aa CvA (P=.248) 0.648 -0.474 1.771
CvM (P=.015) 1.422 0.299 2.545
AvM (P=.170) 0.774 -0.349 1.897
Td CvA (P=.023) -1.318 -2.441 -0.195
CvM (P=.852) -0.104 -1.226 1.019
AvM (P=.035) 1.214 0.091 2.337
Tf CvA (P=.031) 1.246 0.123 2.369
CvM (P=.015) 1.418 0.296 2.541
AvM (P=.756) 0.172 -0.951 1.295
Va CvA (P<.001) -7.124 -8.247 -6.001
CvM (P<.001) -6.170 -7.293 -5.047
AvM (P=.093) 0.954 -0.169 2.077
Sa CvA (P=.470) -0.403 -1.525 0.720
CvM (P=.567) -0.319 -1.441 0.804
AvM (P=.880) 0.084 -1.039 1.207
Sm CvA (P<.001) -3.136 -4.259 -2.013
CvM (P=.015) -1.422 -2.545 -0.300
AvM (P=.004) 1.714 0.591 2.836
Sg CvA (P=.007) -1.586 -2.709 -0.464
CvM (P=.064) -1.058 -2.181 0.065
AvM (P=.344) 0.528 -0.595 1.651
95% CI
Corrected CTBacterial 
species
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Figure 16. Differences in the Corrected CT mean estimates for three H Sets (95% CIs) 
Figure 18 represents the differences in corrected CT mean estimates from the original CT values 
after standardization with 16s primer for Sets 1H, 2H, and 3H combined. ANOVA analysis was 
performed and applied to compare the control group to Amixicile, control group to 
Metronidazole and lastly compare Amixicile and Metronidazole. A “c” represents a statistically 
significant difference from control and antimicrobial. An “x” represents a statistically significant 
difference from Amixicile and Metronidazole.
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Table 15. Corrected CT mean estimates for Set 1D 
Antimicrobials Estimate
Control 31.39 31.16 31.62
Amixicile-c 29.09 28.86 29.32
Metronidazole-c 28.82 28.59 29.05
Control 17.29 17.06 17.52
Amixicile-cx 25.13 24.90 25.36
Metronidazole-cx 25.98 25.75 26.21
Control 23.19 22.96 23.42
Amixicile-cx 24.34 24.11 24.57
Metronidazole-cx 24.87 24.64 25.09
Control 28.03 27.80 28.25
Amixicile-cx 27.47 27.24 27.70
Metronidazole-cx 26.61 26.38 26.84
Control 33.19 32.96 33.42
Amixicile-cx 32.47 32.24 32.70
Metronidazole-x 33.16 32.93 33.39
Control 27.84 27.61 28.07
Amixicile 27.81 27.58 28.04
Metronidazole 27.72 27.49 27.95
Control 26.02 25.79 26.25
Amixicile-cx 27.21 26.98 27.44
Metronidazole-cx 27.71 27.48 27.94
Control 14.62 14.39 14.85
Amixicile-cx 22.72 22.49 22.95
Metronidazole-cx 24.10 23.87 24.33
Control 15.42 15.19 15.65
Amixicile-c 14.95 14.72 15.18
Metronidazole-c 14.88 14.65 15.11
Control 15.32 15.09 15.55
Amixicile-x 15.12 14.89 15.35
Metronidazole-cx 15.74 15.51 15.97
Control 17.71 17.48 17.94
Amixicile-cx 16.74 16.51 16.97
Metronidazole-x 18.03 17.80 18.26
95% CI
Corrected CT
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Figure 17. Corrected CT mean estimates for Set 1D (95% CIs) 
Figure 19 represents the average CT values taken of Set 1D. ANOVA analysis was performed 
and applied to compare the control group to Amixicile, control group to Metronidazole and lastly 
compare Amixicile and Metronidazole. A “c” represents a statistically significant difference 
from control and antimicrobial. An “x” represents a statistically significant difference from 
Amxicile and Metronidazole. 
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Table 16. Differences in the Corrected CT mean estimates for Set 1D 
Compare Estimate
Pg CvA (P<.001) 2.300 1.976 2.624
CvM (P<.001) 2.572 2.248 2.896
AvM (P=.097) 0.272 -0.052 0.596
Pi CvA (P<.001) -7.840 -8.164 -7.515
CvM (P<.001) -8.689 -9.013 -8.364
AvM (P<.001) -0.849 -1.173 -0.525
Fn CvA (P<.001) -1.156 -1.481 -0.832
CvM (P<.001) -1.678 -2.002 -1.354
AvM (P=.003) -0.522 -0.846 -0.197
La CvA (P=.002) 0.555 0.231 0.879
CvM (P<.001) 1.418 1.094 1.742
AvM (P<.001) 0.863 0.539 1.187
Aa CvA (P<.001) 0.721 0.396 1.045
CvM (P=.839) 0.032 -0.292 0.357
AvM (P<.001) -0.688 -1.012 -0.364
Td CvA (P=.815) 0.037 -0.287 0.362
CvM (P=.440) 0.124 -0.200 0.449
AvM (P=.588) 0.087 -0.237 0.411
Tf CvA (P<.001) -1.196 -1.520 -0.872
CvM (P<.001) -1.694 -2.018 -1.369
AvM (P=.004) -0.498 -0.822 -0.173
Va CvA (P<.001) -8.100 -8.425 -7.776
CvM (P<.001) -9.478 -9.802 -9.153
AvM (P<.001) -1.377 -1.702 -1.053
Sa CvA (P=.006) 0.472 0.148 0.796
CvM (P=.002) 0.536 0.212 0.861
AvM (P=.687) 0.065 -0.260 0.389
Sm CvA (P=.222) 0.198 -0.126 0.522
CvM (P=.013) -0.420 -0.745 -0.096
AvM (P<.001) -0.618 -0.943 -0.294
Sg CvA (P<.001) 0.973 0.649 1.298
CvM (P=.057) -0.314 -0.639 0.010
AvM (P<.001) -1.288 -1.612 -0.964
95% CI
Corrected CTBacterial 
species
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Figure 18. Differences in the Corrected CT mean estimates for Set 1D (95% CIs) 
Figure 20 represents the differences in corrected CT mean estimates from the original CT values 
after standardization with 16s primer for Set 1D. ANOVA analysis was performed and applied to 
compare the control group to Amixicile, control group to Metronidazole and lastly compare 
Amixicile and Metronidazole. A “c” represents a statistically significant difference from control 
and antimicrobial. An “x” represents a statistically significant difference from Amixicile and 
Metronidazole. 
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Table 17. Fold Estimates for Set 1D 
 
Antimicrobials Estimate
Pg Amixicile (P<.001) 4.925 3.934 6.167
Metronidazole (P<.001) 5.947 4.750 7.446
Pi Amixicile (P<.001) 0.004 0.003 0.005
Metronidazole (P<.001) 0.002 0.002 0.003
Fn Amixicile (P<.001) 0.449 0.358 0.562
Metronidazole (P<.001) 0.312 0.250 0.391
La Amixicile (P=.002) 1.469 1.173 1.839
Metronidazole (P<.001) 2.672 2.134 3.345
Aa Amixicile (P<.001) 1.648 1.316 2.063
Metronidazole (P=.839) 1.023 0.817 1.281
Td Amixicile (P=.815) 1.026 0.820 1.285
Metronidazole (P=.440) 1.090 0.871 1.365
Tf Amixicile (P<.001) 0.436 0.349 0.546
Metronidazole (P<.001) 0.309 0.247 0.387
Va Amixicile (P<.001) 0.004 0.003 0.005
Metronidazole (P<.001) 0.001 0.001 0.002
Sa Amixicile (P=.006) 1.387 1.108 1.736
Metronidazole (P=.002) 1.450 1.158 1.816
Sm Amixicile (P=.222) 1.147 0.916 1.436
Metronidazole (P=.013) 0.747 0.597 0.936
Sg Amixicile (P<.001) 1.964 1.568 2.458
Metronidazole (P=.057) 0.804 0.642 1.007
95% CI
FoldBacterial 
species
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Figure 19. Fold Estimates for Set 1D (95% CIs) 
Figure 21 represents the fold change observed for Set 1D for bacterial species after treatment of 
either Amixicile or Metronidazole. A P Value <.001 represented a statistical significant change 
in the numbers of bacteria from the control and antimicrobial treatment. 
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Table 18. Corrected CT mean estimates for Set 2D 
 
Antimicrobials Estimate
Pg (P<.001) Control 31.39 31.16 31.62
Amixicile-c 29.09 28.86 29.32
Metronidazole-c 28.82 28.59 29.05
Pi (P<.001) Control 17.29 17.06 17.52
Amixicile-cx 25.13 24.90 25.36
Metronidazole-cx 25.98 25.75 26.21
Fn (P<.001) Control 23.19 22.96 23.42
Amixicile-cx 24.34 24.11 24.57
Metronidazole-cx 24.87 24.64 25.09
La (P<.001) Control 28.03 27.80 28.25
Amixicile-cx 27.47 27.24 27.70
Metronidazole-cx 26.61 26.38 26.84
Aa (P<.001) Control 33.19 32.96 33.42
Amixicile-cx 32.47 32.24 32.70
Metronidazole-x 33.16 32.93 33.39
Td (P=.727) Control 27.84 27.61 28.07
Amixicile 27.81 27.58 28.04
Metronidazole 27.72 27.49 27.95
Tf (P<.001) Control 26.02 25.79 26.25
Amixicile-cx 27.21 26.98 27.44
Metronidazole-cx 27.71 27.48 27.94
Va (P<.001) Control 14.62 14.39 14.85
Amixicile-cx 22.72 22.49 22.95
Metronidazole-cx 24.10 23.87 24.33
Sa (P=.004) Control 15.42 15.19 15.65
Amixicile-c 14.95 14.72 15.18
Metronidazole-c 14.88 14.65 15.11
Sm (P=.002) Control 15.32 15.09 15.55
Amixicile-x 15.12 14.89 15.35
Metronidazole-cx 15.74 15.51 15.97
Sg (P<.001) Control 17.71 17.48 17.94
Amixicile-cx 16.74 16.51 16.97
Metronidazole-x 18.03 17.80 18.26
95% CI
Corrected CTBacterial 
species
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Figure 20. Corrected CT mean estimates for Set 2D (95% CIs) 
Figure 22 represents the average CT values taken of Set 2D. ANOVA analysis was performed 
and applied to compare the control group to Amixicile, control group to Metronidazole and lastly 
compare Amixicile and Metronidazole. A “c” represents a statistically significant difference 
from control and antimicrobial. An “x” represents a statistically significant difference from 
Amxicile and Metronidazole. 
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Table 19:  Differences in the Corrected CT mean estimates for Set 2D 
 
Compare Estimate
Pg CvA (P<.001) 2.300 1.976 2.624
CvM (P<.001) 2.572 2.248 2.896
AvM (P=.097) 0.272 -0.052 0.596
Pi CvA (P<.001) -7.840 -8.164 -7.515
CvM (P<.001) -8.689 -9.013 -8.364
AvM (P<.001) -0.849 -1.173 -0.525
Fn CvA (P<.001) -1.156 -1.481 -0.832
CvM (P<.001) -1.678 -2.002 -1.354
AvM (P=.003) -0.522 -0.846 -0.197
La CvA (P=.002) 0.555 0.231 0.879
CvM (P<.001) 1.418 1.094 1.742
AvM (P<.001) 0.863 0.539 1.187
Aa CvA (P<.001) 0.721 0.396 1.045
CvM (P=.839) 0.032 -0.292 0.357
AvM (P<.001) -0.688 -1.012 -0.364
Td CvA (P=.815) 0.037 -0.287 0.362
CvM (P=.440) 0.124 -0.200 0.449
AvM (P=.588) 0.087 -0.237 0.411
Tf CvA (P<.001) -1.196 -1.520 -0.872
CvM (P<.001) -1.694 -2.018 -1.369
AvM (P=.004) -0.498 -0.822 -0.173
Va CvA (P<.001) -8.100 -8.425 -7.776
CvM (P<.001) -9.478 -9.802 -9.153
AvM (P<.001) -1.377 -1.702 -1.053
Sa CvA (P=.006) 0.472 0.148 0.796
CvM (P=.002) 0.536 0.212 0.861
AvM (P=.687) 0.065 -0.260 0.389
Sm CvA (P=.222) 0.198 -0.126 0.522
CvM (P=.013) -0.420 -0.745 -0.096
AvM (P<.001) -0.618 -0.943 -0.294
Sg CvA (P<.001) 0.973 0.649 1.298
CvM (P=.057) -0.314 -0.639 0.010
AvM (P<.001) -1.288 -1.612 -0.964
95% CI
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Figure 21. Differences in the Corrected CT mean estimates for Set 2D (95% CIs) 
Figure 23 represents the differences in corrected CT mean estimates from the original CT values 
after standardization with 16s primer for Set 2D. ANOVA analysis was performed and applied to 
compare the control group to Amixicile, control group to Metronidazole and lastly compare 
Amixicile and Metronidazole. A “c” represents a statistically significant difference from control 
and antimicrobial. An “x” represents a statistically significant difference from Amixicile and 
Metronidazole. 
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Table 20. Fold Estimates for Set 2D 
 
Antimicrobials Estimate
Pg Amixicile (P<.001) 4.925 3.934 6.167
Metronidazole (P<.001) 5.947 4.750 7.446
Pi Amixicile (P<.001) 0.004 0.003 0.005
Metronidazole (P<.001) 0.002 0.002 0.003
Fn Amixicile (P<.001) 0.449 0.358 0.562
Metronidazole (P<.001) 0.312 0.250 0.391
La Amixicile (P=.002) 1.469 1.173 1.839
Metronidazole (P<.001) 2.672 2.134 3.345
Aa Amixicile (P<.001) 1.648 1.316 2.063
Metronidazole (P=.839) 1.023 0.817 1.281
Td Amixicile (P=.815) 1.026 0.820 1.285
Metronidazole (P=.440) 1.090 0.871 1.365
Tf Amixicile (P<.001) 0.436 0.349 0.546
Metronidazole (P<.001) 0.309 0.247 0.387
Va Amixicile (P<.001) 0.004 0.003 0.005
Metronidazole (P<.001) 0.001 0.001 0.002
Sa Amixicile (P=.006) 1.387 1.108 1.736
Metronidazole (P=.002) 1.450 1.158 1.816
Sm Amixicile (P=.222) 1.147 0.916 1.436
Metronidazole (P=.013) 0.747 0.597 0.936
Sg Amixicile (P<.001) 1.964 1.568 2.458
Metronidazole (P=.057) 0.804 0.642 1.007
95% CI
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 Figure 22. Fold Estimates for Set 2D (95% CIs) 
Figure 24 represents the fold change observed for Set 2D for bacterial species after treatment of 
either Amixicile or Metronidazole. A P Value <.001 represented a statistical significant change 
in the numbers of bacteria from the control and antimicrobial treatment. 
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Table 21. Corrected CT mean estimates for Set 3D 
 
Antimicrobials Estimate
Pg (P=.369) Control 30.46 29.84 31.08
Amixicile 29.95 29.34 30.57
Metronidazole 29.91 29.29 30.52
Pi (P<.001) Control 17.52 16.90 18.13
Amixicile-cx 25.55 24.94 26.17
Metronidazole-cx 26.87 26.25 27.49
Fn (P<.001) Control 22.83 22.21 23.45
Amixicile-c 24.40 23.78 25.02
Metronidazole-c 25.19 24.57 25.80
La (P=.011) Control 28.15 27.53 28.77
Amixicile 27.07 26.45 27.69
Metronidazole-c 26.87 26.25 27.49
Aa (P=.397) Control 33.53 32.92 34.15
Amixicile 33.60 32.98 34.22
Metronidazole 34.08 33.46 34.69
Td (P=.595) Control 28.03 27.42 28.65
Amixicile 27.71 27.09 28.32
Metronidazole 28.12 27.51 28.74
Tf (P=.005) Control 26.29 25.67 26.91
Amixicile-c 27.55 26.94 28.17
Metronidazole-c 27.65 27.03 28.27
Va (P<.001) Control 14.54 13.92 15.16
Amixicile-cx 23.76 23.14 24.37
Metronidazole-cx 25.35 24.74 25.97
Sa (P=.821) Control 15.65 15.03 16.26
Amixicile 15.88 15.26 16.50
Metronidazole 15.88 15.26 16.49
Sm (P=.300) Control 15.33 14.71 15.95
Amixicile 15.25 14.63 15.86
Metronidazole 15.87 15.25 16.49
Sg (P=.001) Control 17.37 16.76 17.99
Amixicile-x 17.01 16.39 17.62
Metronidazole-cx 18.66 18.04 19.28
95% CI
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Figure 23. Corrected CT mean estimates for Set 3D (95% CIs) 
Figure 25 represents the average CT values taken of Set 3D. ANOVA analysis was performed 
and applied to compare the control group to Amixicile, control group to Metronidazole and lastly 
compare Amixicile and Metronidazole. A “c” represents a statistically significant difference 
from control and antimicrobial. An “x” represents a statistically significant difference from 
Amxicile and Metronidazole. 
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Table 22. Differences in the Corrected CT mean estimates for Set 3D 
 
Compare Estimate
Pg CvA (P=.245) 0.507 -0.367 1.381
CvM (P=.205) 0.554 -0.320 1.427
AvM (P=.914) 0.047 -0.827 0.920
Pi CvA (P<.001) -8.038 -8.911 -7.164
CvM (P<.001) -9.352 -10.225 -8.478
AvM (P=.004) -1.314 -2.188 -0.440
Fn CvA (P<.001) -1.574 -2.447 -0.700
CvM (P<.001) -2.359 -3.233 -1.485
AvM (P=.076) -0.786 -1.659 0.088
La CvA (P=.017) 1.084 0.210 1.958
CvM (P=.005) 1.285 0.411 2.158
AvM (P=.643) 0.201 -0.673 1.074
Aa CvA (P=.872) -0.070 -0.943 0.804
CvM (P=.214) -0.543 -1.416 0.331
AvM (P=.277) -0.473 -1.347 0.400
Td CvA (P=.450) 0.328 -0.546 1.201
CvM (P=.834) -0.091 -0.964 0.783
AvM (P=.336) -0.418 -1.292 0.455
Tf CvA (P=.006) -1.264 -2.138 -0.391
CvM (P=.003) -1.360 -2.233 -0.486
AvM (P=.825) -0.095 -0.969 0.778
Va CvA (P<.001) -9.216 -10.090 -8.342
CvM (P<.001) -10.812 -11.686 -9.939
AvM (P<.001) -1.597 -2.470 -0.723
Sa CvA (P=.585) -0.236 -1.110 0.637
CvM (P=.593) -0.231 -1.105 0.642
AvM (P=.991) 0.005 -0.869 0.879
Sm CvA (P=.845) 0.084 -0.789 0.958
CvM (P=.216) -0.540 -1.414 0.333
AvM (P=.155) -0.625 -1.498 0.249
Sg CvA (P=.397) 0.368 -0.506 1.241
CvM (P=.005) -1.289 -2.162 -0.415
AvM (P<.001) -1.656 -2.530 -0.782
95% CI
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Figure 24. Differences in the Corrected CT mean estimates for Set 3D (95% CIs) 
Figure 26 represents the differences in corrected CT mean estimates from the original CT values 
after standardization with 16s primer for Set 3D. ANOVA analysis was performed and applied to 
compare the control group to Amixicile, control group to Metronidazole and lastly compare 
Amixicile and Metronidazole. A “c” represents a statistically significant difference from control 
and antimicrobial. An “x” represents a statistically significant difference from Amixicile and 
Metronidazole. 
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Table 23. Fold Estimates for Set 3D 
 
Antimicrobials Estimate
Pg Amixicile (P=.245) 1.421 0.776 2.604
Metronidazole (P=.205) 1.468 0.801 2.689
Pi Amixicile (P<.001) 0.004 0.002 0.007
Metronidazole (P<.001) 0.002 0.001 0.003
Fn Amixicile (P<.001) 0.336 0.183 0.616
Metronidazole (P<.001) 0.195 0.106 0.357
La Amixicile (P=.017) 2.120 1.157 3.885
Metronidazole (P=.005) 2.436 1.330 4.464
Aa Amixicile (P=.872) 0.953 0.520 1.746
Metronidazole (P=.214) 0.686 0.375 1.258
Td Amixicile (P=.450) 1.255 0.685 2.300
Metronidazole (P=.834) 0.939 0.513 1.721
Tf Amixicile (P=.006) 0.416 0.227 0.763
Metronidazole (P=.003) 0.390 0.213 0.714
Va Amixicile (P<.001) 0.002 0.001 0.003
Metronidazole (P<.001) 0.001 0.000 0.001
Sa Amixicile (P=.585) 0.849 0.463 1.556
Metronidazole (P=.593) 0.852 0.465 1.561
Sm Amixicile (P=.845) 1.060 0.579 1.942
Metronidazole (P=.216) 0.688 0.375 1.260
Sg Amixicile (P=.397) 1.290 0.704 2.364
Metronidazole (P=.005) 0.409 0.223 0.750
95% CI
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Figure 25. Fold Estimates for Set 3D (95% CIs) 
Figure 27 represents the fold change observed for Set 3D for bacterial species after treatment of 
either Amixicile or Metronidazole. A P Value <.001 represented a statistical significant change 
in the numbers of bacteria from the control and antimicrobial treatment. 
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Table 24. Differences in the Corrected CT mean estimates for Sets 1D, 2D, 3D combined 
 
Compare Estimate
Pg CvA (P<.001) 1.208 0.688 1.728
CvM (P<.001) 1.327 0.807 1.847
AvM (P=.645) 0.119 -0.401 0.638
Pi CvA (P<.001) -7.677 -8.197 -7.157
CvM (P<.001) -8.779 -9.299 -8.259
AvM (P<.001) -1.102 -1.622 -0.582
Fn CvA (P<.001) -1.074 -1.594 -0.554
CvM (P<.001) -1.776 -2.295 -1.256
AvM (P=.010) -0.701 -1.221 -0.181
La CvA (P<.001) 1.230 0.710 1.750
CvM (P<.001) 1.417 0.897 1.937
AvM (P=.467) 0.188 -0.332 0.707
Aa CvA (P=.008) 0.718 0.198 1.238
CvM (P=.237) 0.307 -0.213 0.827
AvM (P=.117) -0.411 -0.930 0.109
Td CvA (P=.031) 0.577 0.057 1.097
CvM (P=.420) 0.208 -0.312 0.728
AvM (P=.158) -0.369 -0.889 0.151
Tf CvA (P=.160) -0.367 -0.887 0.153
CvM (P<.001) -1.283 -1.803 -0.764
AvM (P=.001) -0.916 -1.436 -0.396
Va CvA (P<.001) -8.564 -9.083 -8.044
CvM (P<.001) -10.170 -10.690 -9.650
AvM (P<.001) -1.607 -2.127 -1.087
Sa CvA (P=.138) 0.388 -0.131 0.908
CvM (P=.193) 0.339 -0.181 0.859
AvM (P=.848) -0.049 -0.569 0.471
Sm CvA (P=.583) 0.141 -0.378 0.661
CvM (P=.336) -0.249 -0.769 0.271
AvM (P=.136) -0.390 -0.910 0.130
Sg CvA (P=.005) 0.776 0.257 1.296
CvM (P=.128) -0.399 -0.919 0.121
AvM (P<.001) -1.175 -1.695 -0.655
95% CI
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Figure 26. Differences in the Corrected CT mean estimates for Sets 1D, 2D, 3D combined 
Figure 28 represents the differences in corrected CT mean estimates from the original CT values 
after standardization with 16s primer for Sets 1D, 2D, and 3D combined. ANOVA analysis was 
performed and applied to compare the control group to Amixicile, control group to 
Metronidazole and lastly compare Amixicile and Metronidazole. A “c” represents a statistically 
significant difference from control and antimicrobial. An “x” represents a statistically significant 
difference from Amixicile and Metronidazole.
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